PML nuclear bodies in the pathogenesis of acute promyelocytic leukemia: Active players or innocent bystanders?

Frontiers in Bioscience

Volumn 14, Issue 5, 2009, Pages 1684-1707

  Brown, Nicola J M ^a   Ramalho, Michal ^a   Pedersen, Eva W ^a   Moravcsik, Eva ^a   Solomon, Ellen ^a   Grimwade, David ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Nuclear bodies; PML; Promyelocytic leukemia; RARA; Review

Indexed keywords

NUCLEAR PROTEIN; PML PROTEIN, HUMAN; TRANSCRIPTION FACTOR; TUMOR SUPPRESSOR PROTEIN;

CELL NUCLEUS; GENETICS; HUMAN; PATHOPHYSIOLOGY; PHYSIOLOGY; PROMYELOCYTIC LEUKEMIA; REVIEW;

CELL NUCLEUS; HUMANS; LEUKEMIA, PROMYELOCYTIC, ACUTE; NUCLEAR PROTEINS; TRANSCRIPTION FACTORS; TUMOR SUPPRESSOR PROTEINS;

EID: 63849220435     PISSN: 27686701     EISSN: 27686698     Source Type: Journal    
DOI: 10.2741/3333     Document Type: Article

References (194)

1. de The, H., C. Chomienne, M. Lanotte, L. Degos & A. Dejean: The t (15;17) translocation of acute promyelocytic leukaemia fuses the retinoic acid receptor alpha gene to a novel transcribed locus. Nature, 347, 558-61 (1990).
2. Goddard, A. D., J. Borrow, P. S. Freemont & E. Solomon: Characterization of a zinc finger gene disrupted by the t (15;17) in acute promyelocytic leukemia. Science, 254, 1371-4 (1991). (Pubitemid 21917471)
3. Kakizuka, A., W. H. Miller, Jr., K. Umesono, R. P. Warrell, Jr., S. R. Frankel, V. V. Murty, E. Dmitrovsky & R. M. Evans: Chromosomal translocation t (15;17) in human acute promyelocytic leukemia fuses RAR alpha with a novel putative transcription factor, PML. Cell, 66, 663-74 (1991). (Pubitemid 121001702)
4. Pandolfi, P. P., F. Grignani, M. Alcalay, A. Mencarelli, A. Biondi, F. LoCoco & P. G. Pelicci: Structure and origin of the acute promyelocytic leukemia myl/RAR alpha cDNA and characterization of its retinoid-binding and transactivation properties. Oncogene, 6, 1285-92 (1991). (Pubitemid 21924220)
5. Goddard, A. D., J. Borrow & E. Solomon: A previously uncharacterized gene, PML, is fused to the retinoic acid receptor alpha gene in acute promyelocytic leukaemia. Leukemia, 6 Suppl 3, 117S-119S (1992).
6. Nervi, C., E. C. Poindexter, F. Grignani, P. P. Pandolfi, F. Lo Coco, G. Avvisati, P. G. Pelicci & A. M. Jetten: Characterization of the PML-RAR alpha chimeric product of the acute promyelocytic leukemia-specific t (15;17) translocation. Cancer Res, 52, 3687-92 (1992).
7. Bernardi, R. & P. P. Pandolfi: Structure, dynamics and functions of promyelocytic leukaemia nuclear bodies. Nat Rev Mol Cell Biol, 8, 1006-16 (2007). (Pubitemid 350174636)
8. Flenghi, L., M. Fagioli, L. Tomassoni, S. Pileri, M. Gambacorta, R. Pacini, F. Grignani, T. Casini, P. F. Ferrucci, M. F. Martelli & et al.: Characterization of a new monoclonal antibody (PG-M3) directed against the aminoterminal portion of the PML gene product: immunocytochemical evidence for high expression of PML proteins on activated macrophages, endothelial cells, and epithelia. Blood, 85, 1871-80 (1995).
9. Terris, B., V. Baldin, S. Dubois, C. Degott, J. F. Flejou, D. Henin & A. Dejean: PML nuclear bodies are general targets for inflammation and cell proliferation. Cancer Res, 55, 1590-7 (1995).
10. Dyck, J. A., G. G. Maul, W. H. Miller, Jr., J. D. Chen, A. Kakizuka & R. M. Evans: A novel macromolecular structure is a target of the promyelocyte-retinoic acid receptor oncoprotein. Cell, 76, 333-43 (1994). (Pubitemid 24046695)
11. Daniel, M. T., M. Koken, O. Romagne, S. Barbey, A. Bazarbachi, M. Stadler, M. C. Guillemin, L. Degos, C. Chomienne & H. de The: PML protein expression in hematopoietic and acute promyelocytic leukemia cells. Blood, 82, 1858-67 (1993). (Pubitemid 23278777)
12. Regad, T., A. Saib, V. Lallemand-Breitenbach, P. P. Pandolfi, H. de The & M. K. Chelbi-Alix: PML mediates the interferon-induced antiviral state against a complex retrovirus via its association with the viral transactivator. Embo J, 20, 3495-505 (2001). (Pubitemid 32634356)
13. Grimwade, D. & E. Solomon: Characterisation of the PML/RAR alpha rearrangement associated with t (15;17) acute promyelocytic leukaemia. Curr Top Microbiol Immunol, 220, 81-112 (1997). (Pubitemid 27141598)
14. Huang, M. E., Y. C. Ye, S. R. Chen, J. R. Chai, J. X. Lu, L. Zhoa, L. J. Gu & Z. Y. Wang: Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. Blood, 72, 567-72 (1988).
15. Zhu, J., M. H. Koken, F. Quignon, M. K. Chelbi-Alix, L. Degos, Z. Y. Wang, Z. Chen & H. de The: Arsenic-induced PML targeting onto nuclear bodies: implications for the treatment of acute promyelocytic leukemia. Proc Natl Acad Sci U S A, 94, 3978-83 (1997). (Pubitemid 27180484)
16. Wang, Z. G., D. Ruggero, S. Ronchetti, S. Zhong, M. Gaboli, R. Rivi & P. P. Pandolfi: PML is essential for multiple apoptotic pathways. Nat Genet, 20, 266-72 (1998). (Pubitemid 28507671)
17. Wang, Z. G., L. Delva, M. Gaboli, R. Rivi, M. Giorgio, C. Cordon-Cardo, F. Grosveld & P. P. Pandolfi: Role of PML in cell growth and the retinoic acid pathway. Science, 279, 1547-51 (1998). (Pubitemid 28217080)
18. Torii, S., D. A. Egan, R. A. Evans & J. C. Reed: Human Daxx regulates Fas-induced apoptosis from nuclear PML oncogenic domains (PODs). Embo J, 18, 6037-49 (1999). (Pubitemid 29515680)
19. Quignon, F., F. De Bels, M. Koken, J. Feunteun, J. C. Ameisen & H. de The: PML induces a novel caspase-independent death process. Nat Genet, 20, 259-65 (1998). (Pubitemid 28507670)
20. Pearson, M., R. Carbone, C. Sebastiani, M. Cioce, M. Fagioli, S. Saito, Y. Higashimoto, E. Appella, S. Minucci, P. P. Pandolfi & P. G. Pelicci: PML regulates p53 acetylation and premature senescence induced by oncogenic Ras. Nature, 406, 207-10 (2000). (Pubitemid 30469006)
21. Louria-Hayon, I., T. Grossman, R. V. Sionov, O. Alsheich, P. P. Pandolfi & Y. Haupt: The promyelocytic leukemia protein protects p53 from Mdm2-mediated inhibition and degradation. J Biol Chem, 278, 33134-41 (2003). (Pubitemid 37055760)
22. Lin, H. K., S. Bergmann & P. P. Pandolfi: Cytoplasmic PML function in TGF-beta signalling. Nature, 431, 205-11 (2004). (Pubitemid 39243475)
23. Ferbeyre, G., E. de Stanchina, E. Querido, N. Baptiste, C. Prives & S. W. Lowe: PML is induced by oncogenic ras and promotes premature senescence. Genes Dev, 14, 2015-27 (2000). (Pubitemid 30637352)
24. de Stanchina, E., E. Querido, M. Narita, R. V. Davuluri, P. P. Pandolfi, G. Ferbeyre & S. W. Lowe: PML is a direct p53 target that modulates p53 effector functions. Mol Cell, 13, 523-35 (2004). (Pubitemid 38299380)
25. Cohen, N., M. Sharma, A. Kentsis, J. M. Perez, S. Strudwick & K. L. Borden: PML RING suppresses oncogenic transformation by reducing the affinity of eIF4E for mRNA. Embo J, 20, 4547-59 (2001). (Pubitemid 32772048)
26. Chee, A. V., P. Lopez, P. P. Pandolfi & B. Roizman: Promyelocytic leukemia protein mediates interferon-based anti-herpes simplex virus 1 effects. J Virol, 77, 7101-5 (2003). (Pubitemid 36666903)
27. Carlile, G. W., W. G. Tatton & K. L. Borden: Demonstration of a RNA-dependent nuclear interaction between the promyelocytic leukaemia protein and glyceraldehyde-3-phosphate dehydrogenase. Biochem J, 335 ( Pt 3), 691-6 (1998). (Pubitemid 28515425)
28. Freemont. Front Biosci (2008).
29. Fagioli, M., M. Alcalay, P. P. Pandolfi, L. Venturini, A. Mencarelli, A. Simeone, D. Acampora, F. Grignani & P. G. Pelicci: Alternative splicing of PML transcripts predicts coexpression of several carboxy-terminally different protein isoforms. Oncogene, 7, 1083-91 (1992).
30. Beech, S. J., K. J. Lethbridge, N. Killick, N. McGlincy & K. N. Leppard: Isoforms of the promyelocytic leukemia protein differ in their effects on ND10 organization. Exp Cell Res, 307, 109-17 (2005). (Pubitemid 40732737)
31. Condemine, W., Y. Takahashi, J. Zhu, F. Puvion-Dutilleul, S. Guegan, A. Janin & H. de The: Characterization of endogenous human promyelocytic leukemia isoforms. Cancer Res, 66, 6192-8 (2006).
32. Melnick, A. & J. D. Licht: Deconstructing a disease: RARalpha, its fusion partners, and their roles in the pathogenesis of acute promyelocytic leukemia. Blood, 93, 3167-215 (1999). (Pubitemid 29220886)
33. Shen, T. H., H. K. Lin, P. P. Scaglioni, T. M. Yung & P. P. Pandolfi: The mechanisms of PML-nuclear body formation. Mol Cell, 24, 331-9 (2006). (Pubitemid 44647906)
34. Seeler, J. S. & A. Dejean: SUMO: of branched proteins and nuclear bodies. Oncogene, 20, 7243-9 (2001). (Pubitemid 33105013)
35. Miller. Front Biosci (2008).
36. Everett, R. D., P. Lomonte, T. Sternsdorf, R. van Driel & A. Orr: Cell cycle regulation of PML modification and ND10 composition. J Cell Sci, 112 ( Pt 24), 4581-8 (1999). (Pubitemid 30034807)
37. Everett, R. D., W. C. Earnshaw, A. F. Pluta, T. Sternsdorf, A. M. Ainsztein, M. Carmena, S. Ruchaud, W. L. Hsu & A. Orr: A dynamic connection between centromeres and ND10 proteins. J Cell Sci, 112 ( Pt 20), 3443-54 (1999).
38. Chan, J. Y., L. Li, Y. H. Fan, Z. M. Mu, W. W. Zhang & K. S. Chang: Cell-cycle regulation of DNA damage-induced expression of the suppressor gene PML. Biochem Biophys Res Commun, 240, 640-6 (1997). (Pubitemid 28271771)
39. Sternsdorf, T., K. Jensen, B. Reich & H. Will: The nuclear dot protein sp100, characterization of domains necessary for dimerization, subcellular localization, and modification by small ubiquitin-like modifiers. J Biol Chem, 274, 12555-66 (1999).
40. Chan, J. Y., C. L. Meng, K. F. To, S. F. Leung, A. T. Chan, K. K. Lee & P. J. Johnson: Differential expression of the suppressor PML and Ki-67 identifies three subtypes of human nasopharyngeal carcinoma. Eur J Cancer, 38, 1600-6 (2002). (Pubitemid 34876498)
41. Eskiw, C. H., G. Dellaire, J. S. Mymryk & D. P. Bazett-Jones: Size, position and dynamic behavior of PML nuclear bodies following cell stress as a paradigm for supramolecular trafficking and assembly. J Cell Sci, 116, 4455-66 (2003). (Pubitemid 37369600)
42. Borden, K. L.: Pondering the promyelocytic leukemia protein (PML) puzzle: possible functions for PML nuclear bodies. Mol Cell Biol, 22, 5259-69 (2002). (Pubitemid 34755740)
43. Grignani, F., M. Fagioli, M. Alcalay, L. Longo, P. P. Pandolfi, E. Donti, A. Biondi, F. Lo Coco & P. G. Pelicci: Acute promyelocytic leukemia: from genetics to treatment. Blood, 83, 10-25 (1994). (Pubitemid 24016510)
44. Kastner, P., A. Perez, Y. Lutz, C. Rochette-Egly, M. P. Gaub, B. Durand, M. Lanotte, R. Berger & P. Chambon: Structure, localization and transcriptional properties of two classes of retinoic acid receptor alpha fusion proteins in acute promyelocytic leukemia (APL): structural similarities with a new family of oncoproteins. Embo J, 11, 629-42 (1992).
45. de The, H., C. Lavau, A. Marchio, C. Chomienne, L. Degos & A. Dejean: The PML-RAR alpha fusion mRNA generated by the t (15;17) translocation in acute promyelocytic leukemia encodes a functionally altered RAR. Cell, 66, 675-84 (1991). (Pubitemid 121001703)
46. Brown, D., S. Kogan, E. Lagasse, I. Weissman, M. Alcalay, P. G. Pelicci, S. Atwater & J. M. Bishop: A PMLRARalpha transgene initiates murine acute promyelocytic leukemia. Proc Natl Acad Sci U S A, 94, 2551-6 (1997). (Pubitemid 27136913)
47. Koken, M. H., F. Puvion-Dutilleul, M. C. Guillemin, A. Viron, G. Linares-Cruz, N. Stuurman, L. de Jong, C. Szostecki, F. Calvo, C. Chomienne & et al.: The t (15;17) translocation alters a nuclear body in a retinoic acidreversible fashion. Embo J, 13, 1073-83 (1994). (Pubitemid 24074714)
48. Weis, K., S. Rambaud, C. Lavau, J. Jansen, T. Carvalho, M. Carmo-Fonseca, A. Lamond & A. Dejean: Retinoic acid regulates aberrant nuclear localization of PML-RAR alpha in acute promyelocytic leukemia cells. Cell, 76, 345-56 (1994). (Pubitemid 24046696)
49. Freemont, P. S., I. M. Hanson & J. Trowsdale: A novel cysteine-rich sequence motif. Cell, 64, 483-4 (1991).
50. Perez, A., P. Kastner, S. Sethi, Y. Lutz, C. Reibel & P. Chambon: PMLRAR homodimers: distinct DNA binding properties and heteromeric interactions with RXR. Embo J, 12, 3171-82 (1993). (Pubitemid 23232748)
51. Grignani, F., U. Testa, D. Rogaia, P. F. Ferrucci, P. Samoggia, A. Pinto, D. Aldinucci, V. Gelmetti, M. Fagioli, M. Alcalay, J. Seeler, I. Nicoletti, C. Peschle & P. G. Pelicci: Effects on differentiation by the promyelocytic leukemia PML/RARalpha protein depend on the fusion of the PML protein dimerization and RARalpha DNA binding domains. Embo J, 15, 4949-58 (1996). (Pubitemid 26315805)
52. Nervi, C., F. F. Ferrara, M. Fanelli, M. R. Rippo, B. Tomassini, P. F. Ferrucci, M. Ruthardt, V. Gelmetti, C. Gambacorti-Passerini, D. Diverio, F. Grignani, P. G. Pelicci & R. Testi: Caspases mediate retinoic acid-induced degradation of the acute promyelocytic leukemia PML/RARalpha fusion protein. Blood, 92, 2244-51 (1998). (Pubitemid 28452964)
53. Raelson, J. V., C. Nervi, A. Rosenauer, L. Benedetti, Y. Monczak, M. Pearson, P. G. Pelicci & W. H. Miller, Jr.: The PML/RAR alpha oncoprotein is a direct molecular target of retinoic acid in acute promyelocytic leukemia cells. Blood, 88, 2826-32 (1996). (Pubitemid 26357362)
54. Yoshida, H., K. Kitamura, K. Tanaka, S. Omura, T. Miyazaki, T. Hachiya, R. Ohno & T. Naoe: Accelerated degradation of PML-retinoic acid receptor alpha (PMLRARA) oncoprotein by all-trans-retinoic acid in acute promyelocytic leukemia: possible role of the proteasome pathway. Cancer Res, 56, 2945-8 (1996). (Pubitemid 26199737)
55. Chen, G. Q., X. G. Shi, W. Tang, S. M. Xiong, J. Zhu, X. Cai, Z. G. Han, J. H. Ni, G. Y. Shi, P. M. Jia, M. M. Liu, K. L. He, C. Niu, J. Ma, P. Zhang, T. D. Zhang, P. Paul, T. Naoe, K. Kitamura, W. Miller, S. Waxman, Z. Y. Wang, H. de The, S. J. Chen & Z. Chen: Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): I. As2O3 exerts dose-dependent dual effects on APL cells. Blood, 89, 3345-53 (1997). (Pubitemid 27229821)
56. Zhang, T. D., G. Q. Chen, Z. G. Wang, Z. Y. Wang, S. J. Chen & Z. Chen: Arsenic trioxide, a therapeutic agent for APL. Oncogene, 20, 7146-53 (2001). (Pubitemid 33105004)
57. Chen, S. J., A. Zelent, J. H. Tong, H. Q. Yu, Z. Y. Wang, J. Derre, R. Berger, S. Waxman & Z. Chen: Rearrangements of the retinoic acid receptor alpha and promyelocytic leukemia zinc finger genes resulting from t (11;17) (q23;q21) in a patient with acute promyelocytic leukemia. J Clin Invest, 91, 2260-7 (1993). (Pubitemid 23141503)
58. Chen, Z., N. J. Brand, A. Chen, S. J. Chen, J. H. Tong, Z. Y. Wang, S. Waxman & A. Zelent: Fusion between a novel Kruppel-like zinc finger gene and the retinoic acid receptor-alpha locus due to a variant t (11;17) translocation associated with acute promyelocytic leukaemia. Embo J, 12, 1161-7 (1993). (Pubitemid 23095865)
59. Redner, R. L., E. A. Rush, S. Faas, W. A. Rudert & S. J. Corey: The t (5;17) variant of acute promyelocytic leukemia expresses a nucleophosmin- retinoic acid receptor fusion. Blood, 87, 882-6 (1996). (Pubitemid 26043517)
60. Arnould, C., C. Philippe, V. Bourdon, M. J. Gr goire, R. Berger & P. Jonveaux: The signal transducer and activator of transcription STAT5b gene is a new partner of retinoic acid receptor alpha in acute promyelocytic-like leukaemia. Hum Mol Genet, 8, 1741-9 (1999). (Pubitemid 29423884)
61. Wells, R. A., C. Catzavelos & S. Kamel-Reid: Fusion of retinoic acid receptor alpha to NuMA, the nuclear mitotic apparatus protein, by a variant translocation in acute promyelocytic leukaemia. Nat Genet, 17, 109-13 (1997). (Pubitemid 27377543)
62. Redner, R. L., L. C. Contis, F. Craig, C. Evans, M. E. Sherer & S. Shekhter-Levin: A novel t (3;17) (p25;q21) variant translocation of acute promyelocytic leukemia with rearrangement of the RARA locus. Leukemia, 20, 376-9 (2006). (Pubitemid 43148687)
63. Catalano, A., M. A. Dawson, K. Somana, S. Opat, A. Schwarer, L. J. Campbell & H. Iland: The PRKAR1A gene is fused to RARA in a new variant acute promyelocytic leukemia. Blood, 110, 4073-6 (2007). (Pubitemid 350248464)
64. Kondo, T., A. Mori, M. Onozawa, K. Kahata, S. Hashino, J. Tanaka, M. Imamura, M. Morioka & M. Asaka: A Chimeric Gene, FIP1L1-RAR, Is Isolated from t (4;17)-Positive Acute Promyelocytic Leukemia; a Report of Cloning and Functional Analysis. Blood (ASH Annual Meeting Abstracts),, 110, 1820 (2007).
65. Rego, E. M., D. Ruggero, C. Tribioli, G. Cattoretti, S. Kogan, R. L. Redner & P. P. Pandolfi: Leukemia with distinct phenotypes in transgenic mice expressing PML/RAR alpha, PLZF/RAR alpha or NPM/RAR alpha. Oncogene, 25, 1974-9 (2006).
66. Mistry, A. R., E. W. Pedersen, E. Solomon & D. Grimwade: The molecular pathogenesis of acute promyelocytic leukaemia: implications for the clinical management of the disease. Blood Rev, 17, 71-97 (2003). (Pubitemid 36372973)
67. Guidez, F., W. Huang, J. H. Tong, C. Dubois, N. Balitrand, S. Waxman, J. L. Michaux, P. Martiat, L. Degos, Z. Chen & et al.: Poor response to all-trans retinoic acid therapy in a t (11;17) PLZF/RAR alpha patient. Leukemia, 8, 312-7 (1994). (Pubitemid 24057550)
68. Licht, J. D., C. Chomienne, A. Goy, A. Chen, A. A. Scott, D. R. Head, J. L. Michaux, Y. Wu, A. DeBlasio, W. H. Miller, Jr. & et al.: Clinical and molecular characterization of a rare syndrome of acute promyelocytic leukemia associated with translocation (11;17). Blood, 85, 1083-94 (1995).
69. Kitamura, K., S. Hoshi, M. Koike, H. Kiyoi, H. Saito & T. Naoe: Histone deacetylase inhibitor but not arsenic trioxide differentiates acute promyelocytic leukaemia cells with t (11;17) in combination with all-trans retinoic acid. Br J Haematol, 108, 696-702 (2000). (Pubitemid 30304498)
70. Chen, S. Y., L. H. Ma, Y. Dong, W. J. Guo & Z. Y. Wang: (Effects of arsenic trioxide and ATRA on PLZF-RARalpha-positive U937 leukemic cells). Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi, 23, 824-6 (2007).
71. Rego, E. M., L. Z. He, R. P. Warrell, Jr., Z. G. Wang & P. P. Pandolfi: Retinoic acid (RA) and As2O3 treatment in transgenic models of acute promyelocytic leukemia (APL) unravel the distinct nature of the leukemogenic process induced by the PML-RARalpha and PLZF-RARalpha oncoproteins. Proc Natl Acad Sci U S A, 97, 10173-8 (2000).
72. Koken, M. H., M. T. Daniel, M. Gianni, A. Zelent, J. Licht, A. Buzyn, P. Minard, L. Degos, B. Varet & H. de The: Retinoic acid, but not arsenic trioxide, degrades the PLZF/RARalpha fusion protein, without inducing terminal differentiation or apoptosis, in a RA-therapy resistant t (11;17) (q23;q21) APL patient. Oncogene, 18, 1113-8 (1999). (Pubitemid 29086289)
73. Sternsdorf, T., E. Puccetti, K. Jensen, D. Hoelzer, H. Will, O. G. Ottmann & M. Ruthardt: PIC-1/SUMO-1-modified PML-retinoic acid receptor alpha mediates arsenic trioxide-induced apoptosis in acute promyelocytic leukemia. Mol Cell Biol, 19, 5170-8 (1999). (Pubitemid 29289555)
74. Zelent, A., F. Guidez, A. Melnick, S. Waxman & J. D. Licht: Translocations of the RARalpha gene in acute promyelocytic leukemia. Oncogene, 20, 7186-203 (2001). (Pubitemid 33105008)
75. Redner, R. L.: Variations on a theme: the alternate translocations in APL. Leukemia, 16, 1927-32 (2002). (Pubitemid 35203435)
76. Opalinska, J., L. Zhou & A. Verma: A new PML-RARs fusion transcript hints at the important role of PML dysregulation in the pathogenesis of APL. Leuk Lymphoma, 48, 443-4 (2007). (Pubitemid 46487745)
77. Altucci, L., M. D. Leibowitz, K. M. Ogilvie, A. R. de Lera & H. Gronemeyer: RAR and RXR modulation in cancer and metabolic disease. Nat Rev Drug Discov, 6, 793-810 (2007). (Pubitemid 47504871)
78. Minucci, S., M. Maccarana, M. Cioce, P. De Luca, V. Gelmetti, S. Segalla, L. Di Croce, S. Giavara, C. Matteucci, A. Gobbi, A. Bianchini, E. Colombo, I. Schiavoni, G. Badaracco, X. Hu, M. A. Lazar, N. Landsberger, C. Nervi & P. G. Pelicci: Oligomerization of RAR and AML1 transcription factors as a novel mechanism of oncogenic activation. Mol Cell, 5, 811-20 (2000).
79. Qiu, J., Y. Huang, G. Chen, Z. Chen, D. J. Tweardy & S. Dong: Aberrant chromatin remodeling by retinoic acid receptor alpha fusion proteins assessed at the single-cell level. Mol Biol Cell, 18, 3941-51 (2007). (Pubitemid 47519486)
80. Rego, E. M. & P. P. Pandolfi: Reciprocal products of chromosomal translocations in human cancer pathogenesis: key players or innocent bystanders? Trends Mol Med, 8, 396-405 (2002). (Pubitemid 34826726)
81. Rollins, C. T., V. M. Rivera, D. N. Woolfson, T. Keenan, M. Hatada, S. E. Adams, L. J. Andrade, D. Yaeger, M. R. van Schravendijk, D. A. Holt, M. Gilman & T. Clackson: A ligand-reversible dimerization system for controlling protein-protein interactions. Proc Natl Acad Sci U S A, 97, 7096-101 (2000). (Pubitemid 30431423)
82. Zhu, J., R. Nasr, L. Peres, F. Riaucoux-Lormiere, N. Honore, C. Berthier, D. Kamashev, J. Zhou, D. Vitoux, C. Lavau & H. de The: RXR is an essential component of the oncogenic PML/RARA complex in vivo. Cancer Cell, 12, 23-35 (2007). (Pubitemid 47001786)
83. Lin, R. J. & R. M. Evans: Acquisition of oncogenic potential by RAR chimeras in acute promyelocytic leukemia through formation of homodimers. Mol Cell, 5, 821-30 (2000).
84. Villa, R., D. Pasini, A. Gutierrez, L. Morey, M. Occhionorelli, E. Vire, J. F. Nomdedeu, T. Jenuwein, P. G. Pelicci, S. Minucci, F. Fuks, K. Helin & L. Di Croce: Role of the polycomb repressive complex 2 in acute promyelocytic leukemia. Cancer Cell, 11, 513-25 (2007). (Pubitemid 46863505)
85. Hormaeche, I. & J. D. Licht: Chromatin modulation by oncogenic transcription factors: new complexity, new therapeutic targets. Cancer Cell, 11, 475-8 (2007). (Pubitemid 46856913)
86. Heard, E.: Delving into the diversity of facultative heterochromatin: the epigenetics of the inactive X chromosome. Curr Opin Genet Dev, 15, 482-9 (2005). (Pubitemid 41262403)
87. Hernandez-Munoz, I., A. H. Lund, P. van der Stoop, E. Boutsma, I. Muijrers, E. Verhoeven, D. A. Nusinow, B. Panning, Y. Marahrens & M. van Lohuizen: Stable X chromosome inactivation involves the PRC1 Polycomb complex and requires histone MACROH2A1 and the CULLIN3/SPOP ubiquitin E3 ligase. Proc Natl Acad Sci U S A, 102, 7635-40 (2005). (Pubitemid 40741023)
88. Hinkins, M., J. Huntriss, D. Miller & H. M. Picton: Expression of Polycomb-group genes in human ovarian follicles, oocytes and preimplantation embryos. Reproduction, 130, 883-8 (2005). (Pubitemid 41830097)
89. Korf, I., Y. Fan & S. Strome: The Polycomb group in Caenorhabditis elegans and maternal control of germline development. Development, 125, 2469-78 (1998). (Pubitemid 28362407)
90. Kelly, W. G. & A. Fire: Chromatin silencing and the maintenance of a functional germline in Caenorhabditis elegans. Development, 125, 2451-6 (1998). (Pubitemid 28362405)
91. Lessard, J., S. Baban & G. Sauvageau: Stage-specific expression of polycomb group genes in human bone marrow cells. Blood, 91, 1216-24 (1998). (Pubitemid 28086874)
92. Takihara, Y. & J. Hara: Polycomb-group genes and hematopoiesis. Int J Hematol, 72, 165-72 (2000).
93. Lessard, J. & G. Sauvageau: Polycomb group genes as epigenetic regulators of normal and leukemic hemopoiesis. Exp Hematol, 31, 567-85 (2003). (Pubitemid 36808800)
94. Raaphorst, F. M.: Self-renewal of hematopoietic and leukemic stem cells: a central role for the Polycomb-group gene Bmi-1. Trends Immunol, 24, 522-4 (2003). (Pubitemid 37205201)
95. Zeisig, B. B., C. Kwok, A. Zelent, P. Shankaranarayanan, H. Gronemeyer, S. Dong & C. W. So: Recruitment of RXR by homotetrameric RARalpha fusion proteins is essential for transformation. Cancer Cell, 12, 36-51 (2007). (Pubitemid 47018239)
96. Minucci, S. & P. G. Pelicci: Determinants of oncogenic transformation in acute promyelocytic leukemia: the hetero-union makes the force. Cancer Cell, 12, 1-3 (2007). (Pubitemid 47001790)
97. Sternsdorf, T., V. T. Phan, M. L. Maunakea, C. B. Ocampo, J. Sohal, A. Silletto, F. Galimi, M. M. Le Beau, R. M. Evans & S. C. Kogan: Forced retinoic acid receptor alpha homodimers prime mice for APL-like leukemia. Cancer Cell, 9, 81-94 (2006). (Pubitemid 43202659)
98. Altabef, M., M. Garcia, C. Lavau, S. C. Bae, A. Dejean & J. Samarut: A retrovirus carrying the promyelocyteretinoic acid receptor PML-RARalpha fusion gene transforms haematopoietic progenitors in vitro and induces acute leukaemias. Embo J, 15, 2707-16 (1996). (Pubitemid 26176248)
99. Licht, J. D.: Reconstructing a disease: What essential features of the retinoic acid receptor fusion oncoproteins generate acute promyelocytic leukemia? Cancer Cell, 9, 73-4 (2006). (Pubitemid 43202656)
100. Matsushita, H., P. P. Scaglioni, M. Bhaumik, E. M. Rego, L. F. Cai, S. M. Majid, H. Miyachi, A. Kakizuka, W. H. Miller, Jr. & P. P. Pandolfi: In vivo analysis of the role of aberrant histone deacetylase recruitment and RAR alpha blockade in the pathogenesis of acute promyelocytic leukemia. J Exp Med, 203, 821-8 (2006).
101. Donehower, L. A.: The p53-deficient mouse: a model for basic and applied cancer studies. Semin Cancer Biol, 7, 269-78 (1996). (Pubitemid 27182786)
102. Rego, E. M., Z. G. Wang, D. Peruzzi, L. Z. He, C. Cordon-Cardo & P. P. Pandolfi: Role of promyelocytic leukemia (PML) protein in tumor suppression. J Exp Med, 193, 521-29 (2001). (Pubitemid 32524482)
103. Salomoni, P. & P. P. Pandolfi: The role of PML in tumor suppression. Cell, 108, 165-70 (2002). (Pubitemid 34161137)
104. Koken, M. H., G. Linares-Cruz, F. Quignon, A. Viron, M. K. Chelbi-Alix, J. Sobczak-Thepot, L. Juhlin, L. Degos, F. Calvo & H. de The: The PML growth-suppressor has an altered expression in human oncogenesis. Oncogene, 10, 1315-24 (1995).
105. Mu, Z. M., X. F. Le, S. Vallian, A. B. Glassman & K. S. Chang: Stable overexpression of PML alters regulation of cell cycle progression in HeLa cells. Carcinogenesis, 18, 2063-9 (1997). (Pubitemid 28134730)
106. Gurrieri, C., P. Capodieci, R. Bernardi, P. P. Scaglioni, K. Nafa, L. J. Rush, D. A. Verbel, C. Cordon-Cardo & P. P. Pandolfi: Loss of the tumor suppressor PML in human cancers of multiple histologic origins. J Natl Cancer Inst, 96, 269-79 (2004). (Pubitemid 38256272)
107. Scaglioni, P. P., T. M. Yung, L. F. Cai, H. Erdjument- Bromage, A. J. Kaufman, B. Singh, J. Teruya-Feldstein, P. Tempst & P. P. Pandolfi: A CK2-dependent mechanism for degradation of the PML tumor suppressor. Cell, 126, 269-83 (2006). (Pubitemid 44092959)
108. Armstrong, J. L., G. A. Taylor, H. D. Thomas, A. V. Boddy, C. P. Redfern & G. J. Veal: Molecular targeting of retinoic acid metabolism in neuroblastoma: the role of the CYP26 inhibitor R116010 in vitro and in vivo. Br J Cancer, 96, 1675-83 (2007). (Pubitemid 46847203)
109. Yu, J. H., A. Nakajima, H. Nakajima, L. R. Diller, K. D. Bloch & D. B. Bloch: Restoration of promyelocytic leukemia protein-nuclear bodies in neuroblastoma cells enhances retinoic acid responsiveness. Cancer Res, 64, 928-33 (2004). (Pubitemid 38176894)
110. Gurrieri, C., K. Nafa, T. Merghoub, R. Bernardi, P. Capodieci, A. Biondi, S. Nimer, D. Douer, C. Cordon- Cardo, R. Gallagher & P. P. Pandolfi: Mutations of the PML tumor suppressor gene in acute promyelocytic leukemia. Blood, 103, 2358-62 (2004). (Pubitemid 38326258)
111. Bellodi, C., K. Kindle, F. Bernassola, D. Dinsdale, A. Cossarizza, G. Melino, D. Heery & P. Salomoni: Cytoplasmic function of mutant promyelocytic leukemia (PML) and PML-retinoic acid receptor-alpha. J Biol Chem, 281, 14465-73 (2006). (Pubitemid 43848377)
112. Khan, M. M., T. Nomura, T. Chiba, K. Tanaka, H. Yoshida, K. Mori & S. Ishii: The fusion oncoprotein PMLRARalpha induces endoplasmic reticulum (ER)-associated degradation of N-CoR and ER stress. J Biol Chem, 279, 11814-24 (2004). (Pubitemid 38401686)
113. Maul, G. G., D. Negorev, P. Bell & A. M. Ishov: Review: properties and assembly mechanisms of ND10, PML bodies, or PODs. J Struct Biol, 129, 278-87 (2000). (Pubitemid 30481369)
114. Negorev, D. & G. G. Maul: Cellular proteins localized at and interacting within ND10/PML nuclear bodies/PODs suggest functions of a nuclear depot. Oncogene, 20, 7234-42 (2001). (Pubitemid 33105012)
115. Bischof, O., O. Kirsh, M. Pearson, K. Itahana, P. G. Pelicci & A. Dejean: Deconstructing PML-induced premature senescence. Embo J, 21, 3358-69 (2002). (Pubitemid 34760568)
116. Guo, A., P. Salomoni, J. Luo, A. Shih, S. Zhong, W. Gu & P. P. Pandolfi: The function of PML in p53- dependent apoptosis. Nat Cell Biol, 2, 730-6 (2000).
117. Zhong, S., P. Hu, T. Z. Ye, R. Stan, N. A. Ellis & P. P. Pandolfi: A role for PML and the nuclear body in genomic stability. Oncogene, 18, 7941-7 (1999). (Pubitemid 30050554)
118. Hoemme, C., A. Peerzada, G. Behre, Y. Wang, M. McClelland, K. Nieselt, M. Zschunke, C. Disselhoff, S. Agrawal, F. Isken, N. Tidow, W. E. Berdel, H. Serve & C. Muller-Tidow: Chromatin modifications induced by PMLRAR{ alpha} repress critical targets in leukemogenesis as analyzed by ChIP-Chip. Blood, 111, 2887-95 (2008).
119. Walter, M. J., J. S. Park, S. K. Lau, X. Li, A. A. Lane, R. Nagarajan, W. D. Shannon & T. J. Ley: Expression profiling of murine acute promyelocytic leukemia cells reveals multiple model-dependent progression signatures. Mol Cell Biol, 24, 10882-93 (2004). (Pubitemid 39603143)
120. Kalantry, S., L. Delva, M. Gaboli, D. Gandini, M. Giorgio, N. Hawe, L. Z. He, D. Peruzzi, R. Rivi, C. Tribioli, Z. G. Wang, H. Zhang & P. P. Pandolfi: Gene rearrangements in the molecular pathogenesis of acute promyelocytic leukemia. J Cell Physiol, 173, 288-96 (1997). (Pubitemid 27481147)
121. Yoshida, H., H. Ichikawa, Y. Tagata, T. Katsumoto, K. Ohnishi, Y. Akao, T. Naoe, P. P. Pandolfi & I. Kitabayashi: PML-retinoic acid receptor alpha inhibits PML IV enhancement of PU.1-induced C/EBPepsilon expression in myeloid differentiation. Mol Cell Biol, 27, 5819-34 (2007). (Pubitemid 47257836)
122. Hanson, R. W.: Biological role of the isoforms of C/EBP minireview series. J Biol Chem, 273, 28543 (1998). (Pubitemid 28507531)
123. Yeamans, C., D. Wang, I. Paz-Priel, B. E. Torbett, D. G. Tenen & A. D. Friedman: C/EBPalpha binds and activates the PU.1 distal enhancer to induce monocyte lineage commitment. Blood, 110, 3136-42 (2007). (Pubitemid 350106304)
124. Stirewalt, D. L.: Fine-tuning PU.1. Nat Genet, 36, 550-1 (2004). (Pubitemid 38715976)
125. Rosenbauer, F., K. Wagner, J. L. Kutok, H. Iwasaki, M. M. Le Beau, Y. Okuno, K. Akashi, S. Fiering & D. G. Tenen: Acute myeloid leukemia induced by graded reduction of a lineage-specific transcription factor, PU.1. Nat Genet, 36, 624-30 (2004). (Pubitemid 38715991)
126. Borden, K. L. Front Biosci(2008).
127. Strudwick, S. & K. L. Borden: The emerging roles of translation factor eIF4E in the nucleus. Differentiation, 70, 10-22 (2002). (Pubitemid 38232695)
128. Lai, H. K. & K. L. Borden: The promyelocytic leukemia (PML) protein suppresses cyclin D1 protein production by altering the nuclear cytoplasmic distribution of cyclin D1 mRNA. Oncogene, 19, 1623-34 (2000). (Pubitemid 30200964)
129. Lejbkowicz, F., C. Goyer, A. Darveau, S. Neron, R. Lemieux & N. Sonenberg: A fraction of the mRNA 5' capbinding protein, eukaryotic initiation factor 4E, localizes to the nucleus. Proc Natl Acad Sci U S A, 89, 9612-6 (1992).
130. Lang, V., N. I. Zanchin, H. Lunsdorf, M. Tuite & J. E. McCarthy: Initiation factor eIF-4E of Saccharomyces cerevisiae. Distribution within the cell, binding to mRNA, and consequences of its overproduction. J Biol Chem, 269, 6117-23 (1994).
131. Hanna, J., A. Meides, D. P. Zhang & D. Finley: A ubiquitin stress response induces altered proteasome composition. Cell, 129, 747-59 (2007). (Pubitemid 46802382)
132. Lin, H. K., S. Altuwaijri, W. J. Lin, P. Y. Kan, L. L. Collins & C. Chang: Proteasome activity is required for androgen receptor transcriptional activity via regulation of androgen receptor nuclear translocation and interaction with coregulators in prostate cancer cells. J Biol Chem, 277, 36570-6 (2002).
133. Lee, D. H. & A. L. Goldberg: Proteasome inhibitors: valuable new tools for cell biologists. Trends Cell Biol, 8, 397-403 (1998). (Pubitemid 28458705)
134. Freemont, P. S.: RING for destruction? Curr Biol, 10, R84-7 (2000).
135. Everett, R. D., M. Meredith, A. Orr, A. Cross, M. Kathoria & J. Parkinson: A novel ubiquitin-specific protease is dynamically associated with the PML nuclear domain and binds to a herpesvirus regulatory protein. Embo J, 16, 566-77 (1997). (Pubitemid 27067786)
136. Lallemand-Breitenbach, V., J. Zhu, F. Puvion, M. Koken, N. Honore, A. Doubeikovsky, E. Duprez, P. P. Pandolfi, E. Puvion, P. Freemont & H. de The: Role of promyelocytic leukemia (PML) sumolation in nuclear body formation, 11S proteasome recruitment, and As2O3-induced PML or PML/retinoic acid receptor alpha degradation. J Exp Med, 193, 1361-71 (2001). (Pubitemid 32565965)
137. Wei, X., Z. K. Yu, A. Ramalingam, S. R. Grossman, J. H. Yu, D. B. Bloch & C. G. Maki: Physical and functional interactions between PML and MDM2. J Biol Chem, 278, 29288-97 (2003). (Pubitemid 36935845)
138. Zhu, J., J. Zhou, L. Peres, F. Riaucoux, N. Honore, S. Kogan & H. de The: A sumoylation site in PML/RARA is essential for leukemic transformation. Cancer Cell, 7, 143-53 (2005). (Pubitemid 40248340)
139. Hecker, C. M., M. Rabiller, K. Haglund, P. Bayer & I. Dikic: Specification of SUMO1- and SUMO2-interacting motifs. J Biol Chem, 281, 16117-27 (2006). (Pubitemid 43848507)
140. Saitoh, N., Y. Uchimura, T. Tachibana, S. Sugahara, H. Saitoh & M. Nakao: In situ SUMOylation analysis reveals a modulatory role of RanBP2 in the nuclear rim and PML bodies. Exp Cell Res, 312, 1418-30 (2006).
141. Quimby, B. B., V. Yong-Gonzalez, T. Anan, A. V. Strunnikov & M. Dasso: The promyelocytic leukemia protein stimulates SUMO conjugation in yeast. Oncogene, 25, 2999-3005 (2006). (Pubitemid 43780464)
142. Perlman, R., W. P. Schiemann, M. W. Brooks, H. F. Lodish & R. A. Weinberg: TGF-beta-induced apoptosis is mediated by the adapter protein Daxx that facilitates JNK activation. Nat Cell Biol, 3, 708-14 (2001). (Pubitemid 32734248)
143. Ecsedy, J. A., J. S. Michaelson & P. Leder: Homeodomain-interacting protein kinase 1 modulates Daxx localization, phosphorylation, and transcriptional activity. Mol Cell Biol, 23, 950-60 (2003). (Pubitemid 36133513)
144. Zhong, S., P. Salomoni, S. Ronchetti, A. Guo, D. Ruggero & P. P. Pandolfi: Promyelocytic leukemia protein (PML) and Daxx participate in a novel nuclear pathway for apoptosis. J Exp Med, 191, 631-40 (2000).
145. Ishov, A. M., A. G. Sotnikov, D. Negorev, O. V. Vladimirova, N. Neff, T. Kamitani, E. T. Yeh, J. F. Strauss, 3rd & G. G. Maul: PML is critical for ND10 formation and recruits the PML-interacting protein daxx to this nuclear structure when modified by SUMO-1. J Cell Biol, 147, 221-34 (1999).
146. Li, H., C. Leo, J. Zhu, X. Wu, J. O'Neil, E. J. Park & J. D. Chen: Sequestration and inhibition of Daxx-mediated transcriptional repression by PML. Mol Cell Biol, 20, 1784-96 (2000). (Pubitemid 30100196)
147. Hollenbach, A. D., C. J. McPherson, E. J. Mientjes, R. Iyengar & G. Grosveld: Daxx and histone deacetylase II associate with chromatin through an interaction with core histones and the chromatin-associated protein Dek. J Cell Sci, 115, 3319-30 (2002). (Pubitemid 34960184)
148. Milovic-Holm, K., E. Krieghoff, K. Jensen, H. Will & T. G. Hofmann: FLASH links the CD95 signaling pathway to the cell nucleus and nuclear bodies. Embo J, 26, 391-401 (2007). (Pubitemid 46160940)
149. Krieghoff, E., K. Milovic-Holm & T. G. Hofmann: FLASH meets nuclear bodies: CD95 receptor signals via a nuclear pathway. Cell Cycle, 6, 771-5 (2007). (Pubitemid 46572611)
150. Sanchez-Pulido, L., A. Valencia & A. M. Rojas: Are promyelocytic leukaemia protein nuclear bodies a scaffold for caspase-2 programmed cell death? Trends Biochem Sci, 32, 400-6 (2007). (Pubitemid 47376813)
151. Will, H. Front Biosci (2008).
152. Miller, T. M., K. L. Moulder, C. M. Knudson, D. J. Creedon, M. Deshmukh, S. J. Korsmeyer & E. M. Johnson, Jr.: Bax deletion further orders the cell death pathway in cerebellar granule cells and suggests a caspase-independent pathway to cell death. J Cell Biol, 139, 205-17 (1997). (Pubitemid 27444092)
153. Monney, L., I. Otter, R. Olivier, H. L. Ozer, A. L. Haas, S. Omura & C. Borner: Defects in the ubiquitin pathway induce caspase-independent apoptosis blocked by Bcl-2. J Biol Chem, 273, 6121-31 (1998). (Pubitemid 28144692)
154. Hu, P., S. F. Beresten, A. J. van Brabant, T. Z. Ye, P. P. Pandolfi, F. B. Johnson, L. Guarente & N. A. Ellis: Evidence for BLM and Topoisomerase IIIalpha interaction in genomic stability. Hum Mol Genet, 10, 1287-98 (2001). (Pubitemid 32600482)
155. Xu, Z. X., A. Timanova-Atanasova, R. X. Zhao & K. S. Chang: PML colocalizes with and stabilizes the DNA damage response protein TopBP1. Mol Cell Biol, 23, 4247-56 (2003). (Pubitemid 36666427)
156. Shay, J. W.: Molecular pathogenesis of aging and cancer: are telomeres and telomerase the connection? J Clin Pathol, 50, 799-800 (1997).
157. Shay, J. W.: Telomerase in human development and cancer. J Cell Physiol, 173, 266-70 (1997). (Pubitemid 27481142)
158. Shay, J. W. & S. Bacchetti: A survey of telomerase activity in human cancer. Eur J Cancer, 33, 787-91 (1997).
159. Yeager, T. R., A. A. Neumann, A. Englezou, L. I. Huschtscha, J. R. Noble & R. R. Reddel: Telomerase-negative immortalized human cells contain a novel type of promyelocytic leukemia (PML) body. Cancer Res, 59, 4175-9 (1999). (Pubitemid 29418720)
160. Whitaker, N. J., T. M. Bryan, P. Bonnefin, A. C. Chang, E. A. Musgrove, A. W. Braithwaite & R. R. Reddel: Involvement of RB-1, p53, p16INK4 and telomerase in immortalisation of human cells. Oncogene, 11, 971-6 (1995).
161. Dandjinou, A. T., I. Dionne, S. Gravel, C. LeBel, J. Parenteau & R. J. Wellinger: Cytological and functional aspects of telomere maintenance. Histol Histopathol, 14, 517-24 (1999). (Pubitemid 29159021)
162. Lundblad, V. & E. H. Blackburn: An alternative pathway for yeast telomere maintenance rescues est1-senescence. Cell, 73, 347-60 (1993). (Pubitemid 23123312)
163. Eskiw, C. H., G. Dellaire & D. P. Bazett-Jones: Chromatin contributes to structural integrity of promyelocytic leukemia bodies through a SUMO-1-independent mechanism. J Biol Chem, 279, 9577-85 (2004). (Pubitemid 38296026)
164. Blondel, D., T. Regad, N. Poisson, B. Pavie, F. Harper, P. P. Pandolfi, H. De The & M. K. Chelbi-Alix: Rabies virus P and small P products interact directly with PML and reorganize PML nuclear bodies. Oncogene, 21, 7957-70 (2002). (Pubitemid 35430607)
165. Bonilla, W. V., D. D. Pinschewer, P. Klenerman, V. Rousson, M. Gaboli, P. P. Pandolfi, R. M. Zinkernagel, M. S. Salvato & H. Hengartner: Effects of promyelocytic leukemia protein on virus-host balance. J Virol, 76, 3810-8 (2002). (Pubitemid 34250546)
166. Kumar, P. P., O. Bischof, P. K. Purbey, D. Notani, H. Urlaub, A. Dejean & S. Galande: Functional interaction between PML and SATB1 regulates chromatin-loop architecture and transcription of the MHC class I locus. Nat Cell Biol, 9, 45-56 (2007). (Pubitemid 46024196)
167. Zhong, S., P. Salomoni & P. P. Pandolfi: The transcriptional role of PML and the nuclear body. Nat Cell Biol, 2, E85-90 (2000).
168. Zhong, S., L. Delva, C. Rachez, C. Cenciarelli, D. Gandini, H. Zhang, S. Kalantry, L. P. Freedman & P. P. Pandolfi: A RA-dependent, tumour-growth suppressive transcription complex is the target of the PML-RARalpha and T18 oncoproteins. Nat Genet, 23, 287-95 (1999). (Pubitemid 29526425)
169. Guiochon-Mantel, A., J. F. Savouret, F. Quignon, K. Delabre, E. Milgrom & H. De The: Effect of PML and PML-RAR on the transactivation properties and subcellular distribution of steroid hormone receptors. Mol Endocrinol, 9, 1791-803 (1995).
170. Luciani, J. J., D. Depetris, Y. Usson, C. Metzler- Guillemain, C. Mignon-Ravix, M. J. Mitchell, A. Megarbane, P. Sarda, H. Sirma, A. Moncla, J. Feunteun & M. G. Mattei: PML nuclear bodies are highly organised DNA-protein structures with a function in heterochromatin remodelling at the G2 phase. J Cell Sci, 119, 2518-31 (2006). (Pubitemid 44070433)
171. Seeler, J. S., A. Marchio, D. Sitterlin, C. Transy & A. Dejean: Interaction of SP100 with HP1 proteins: a link between the promyelocytic leukemia-associated nuclear bodies and the chromatin compartment. Proc Natl Acad Sci U S A, 95, 7316-21 (1998). (Pubitemid 28293249)
172. Tashiro, S., A. Muto, K. Tanimoto, H. Tsuchiya, H. Suzuki, H. Hoshino, M. Yoshida, J. Walter & K. Igarashi: Repression of PML nuclear body-associated transcription by oxidative stress-activated Bach2. Mol Cell Biol, 24, 3473-84 (2004). (Pubitemid 38452086)
173. Kiesslich, A., A. von Mikecz & P. Hemmerich: Cell cycle-dependent association of PML bodies with sites of active transcription in nuclei of mammalian cells. J Struct Biol, 140, 167-79 (2002). (Pubitemid 36139858)
174. Grimwade, D., P. Gorman, E. Duprez, K. Howe, S. Langabeer, F. Oliver, H. Walker, D. Culligan, J. Waters, M. Pomfret, A. Goldstone, A. Burnett, P. Freemont, D. Sheer & E. Solomon: Characterization of cryptic rearrangements and variant translocations in acute promyelocytic leukemia. Blood, 90, 4876-85 (1997). (Pubitemid 28007201)
175. Ruthardt, M., A. Orleth, L. Tomassoni, E. Puccetti, D. Riganelli, M. Alcalay, R. Mannucci, I. Nicoletti, F. Grignani, M. Fagioli & P. G. Pelicci: The acute promyelocytic leukaemia specific PML and PLZF proteins localize to adjacent and functionally distinct nuclear bodies. Oncogene, 16, 1945-53 (1998). (Pubitemid 28200606)
176. Koken, M. H., A. Reid, F. Quignon, M. K. Chelbi- Alix, J. M. Davies, J. H. Kabarowski, J. Zhu, S. Dong, S. Chen, Z. Chen, C. C. Tan, J. Licht, S. Waxman, H. de The & A. Zelent: Leukemia-associated retinoic acid receptor alpha fusion partners, PML and PLZF, heterodimerize and colocalize to nuclear bodies. Proc Natl Acad Sci U S A, 94, 10255-60 (1997).
177. Grimwade, D., A. Biondi, M. J. Mozziconacci, A. Hagemeijer, R. Berger, M. Neat, K. Howe, N. Dastugue, J. Jansen, I. Radford-Weiss, F. Lo Coco, M. Lessard, J. M. Hernandez, E. Delabesse, D. Head, V. Liso, D. Sainty, G. Flandrin, E. Solomon, F. Birg & M. Lafage-Pochitaloff: Characterization of acute promyelocytic leukemia cases lacking the classic t (15;17): results of the European Working Party. Groupe Francais de Cytogenetique Hematologique, Groupe de Francais d'Hematologie Cellulaire, UK Cancer Cytogenetics Group and BIOMED 1 European Community-Concerted Action "Molecular Cytogenetic Diagnosis in Haematological Malignancies". Blood, 96, 1297-308 (2000). (Pubitemid 30658458)
178. Redner, R. L., S. J. Corey & E. A. Rush: Differentiation of t (5;17) variant acute promyelocytic leukemic blasts by all-trans retinoic acid. Leukemia, 11, 1014-6 (1997). (Pubitemid 27345950)
179. Hayflick, L. & P. S. Moorhead: The serial cultivation of human diploid cell strains. Exp Cell Res, 25, 585-621 (1961).
180. Best, J. L., S. Ganiatsas, S. Agarwal, A. Changou, P. Salomoni, O. Shirihai, P. B. Meluh, P. P. Pandolfi & L. I. Zon: SUMO-1 protease-1 regulates gene transcription through PML. Mol Cell, 10, 843-55 (2002). (Pubitemid 35335639)
181. Park, D. J., P. T. Vuong, S. de Vos, D. Douer & H. P. Koeffler: Comparative analysis of genes regulated by PML/RAR alpha and PLZF/RAR alpha in response to retinoic acid using oligonucleotide arrays. Blood, 102, 3727-36 (2003). (Pubitemid 37409394)
182. Salomoni, P. & C. Bellodi: New insights into the cytoplasmic function of PML. Histol Histopathol, 22, 937-46 (2007). (Pubitemid 47034159)
183. Le, X. F., P. Yang & K. S. Chang: Analysis of the growth and transformation suppressor domains of promyelocytic leukemia gene, PML. J Biol Chem, 271, 130-5 (1996). (Pubitemid 26026568)
184. Lin, H. K., S. Bergmann & P. P. Pandolfi: Deregulated TGF-beta signaling in leukemogenesis. Oncogene, 24, 5693-700 (2005).
185. Piek, E., C. H. Heldin & P. Ten Dijke: Specificity, diversity, and regulation in TGF-beta superfamily signaling. Faseb J, 13, 2105-24 (1999).
186. Wrana, J. L.: Regulation of Smad activity. Cell, 100, 189-92 (2000). (Pubitemid 30064906)
187. Shi, Y. & J. Massague: Mechanisms of TGF-beta signaling from cell membrane to the nucleus. Cell, 113, 685-700 (2003). (Pubitemid 36724933)
188. Duprez, E., A. J. Saurin, J. M. Desterro, V. Lallemand-Breitenbach, K. Howe, M. N. Boddy, E. Solomon, H. de The, R. T. Hay & P. S. Freemont: SUMO-1 modification of the acute promyelocytic leukaemia protein PML: implications for nuclear localisation. J Cell Sci, 112 ( Pt 3), 381-93 (1999). (Pubitemid 29080660)
189. Fuchsova, B., P. Novak, J. Kafkova & P. Hozak: Nuclear DNA helicase II is recruited to IFN-alpha-activated transcription sites at PML nuclear bodies. J Cell Biol, 158, 463-73 (2002). (Pubitemid 34851705)
190. LaMorte, V. J., J. A. Dyck, R. L. Ochs & R. M. Evans: Localization of nascent RNA and CREB binding protein with the PML-containing nuclear body. Proc Natl Acad Sci U S A, 95, 4991-6 (1998).
191. Boisvert, F. M., M. J. Hendzel & D. P. Bazett-Jones: Promyelocytic leukemia (PML) nuclear bodies are protein structures that do not accumulate RNA. J Cell Biol, 148, 283-92 (2000). (Pubitemid 30078240)
192. von Mikecz, A., S. Zhang, M. Montminy, E. M. Tan & P. Hemmerich: CREB-binding protein (CBP)/p300 and RNA polymerase II colocalize in transcriptionally active domains in the nucleus. J Cell Biol, 150, 265-73 (2000). (Pubitemid 30480242)
193. Grande, M. A., I. van der Kraan, B. van Steensel, W. Schul, H. de The, H. T. van der Voort, L. de Jong & R. van Driel: PML-containing nuclear bodies: their spatial distribution in relation to other nuclear components. J Cell Biochem, 63, 280-91 (1996). (Pubitemid 26371554)
194. de Jong, L., M. A. Grande, K. A. Mattern, W. Schul & R. van Driel: Nuclear domains involved in RNA synthesis, RNA processing, and replication. Crit Rev Eukaryot Gene Expr, 6, 215-46 (1996). (Pubitemid 26275308)